—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Crispr Therapeutics AG (CRSP) — chart, structure and Closelooknet read

The Closelooknet read

Crispr Therapeutics builds gene-editing medicines around its CRISPR/Cas9 platform, altering specific DNA sequences to treat serious diseases. Its lead product, Casgevy, edits a patient's own stem cells to treat sickle cell disease and beta-thalassemia, developed with partner Vertex Pharmaceuticals.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Research diary readings, not advice.

Pick a ticker to load its detail page.

The desk on CRSP

What this diary said about Crispr Therapeutics AG, what it holds and what would change its view — in its own words, dated. Investment diary, not advice.

What we said

Signals for this name

Every Closelooknet reading that exists for CRSP, from the same nightly bakes the boards use. Research diary readings, not advice.

Mentioned on Closelooknet 2 pieces · newest: Strategy, “Portfolio Construction — The Barbell Architecture, Why the Middle Is Decay” (2026-05-23)

Mentioned on Closelooknet

Where CRSP appears in the diary — 2 pieces, newest first. Every link is our own writing.

Long reads

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 46/100 · S&P 500 fund at 49, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-30
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 81th percentile of the window, -13.7% over 20 sessions. Factor regime → 2026-10-29
  • Sovereign pressure Index -1.66 · down 2.24 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-30
How it trades on rate days beta 1.63 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How CRSP has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 1.63 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Crispr Therapeutics AG moved 1.63% on average · correlation 0.27 · higher than 97% of US names
  • Beta, last 3 months 1.77 about the same as over the year
  • On the 10 worst bond days −2.60% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −0.11% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against CRSP on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Crispr Therapeutics AG

CRSP in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Crispr Therapeutics builds gene-editing medicines around its CRISPR/Cas9 platform, altering specific DNA sequences to treat serious diseases. Its lead product, Casgevy, edits a patient's own stem cells to treat sickle cell disease and beta-thalassemia, developed with partner Vertex Pharmaceuticals. The pipeline extends into CAR T cell therapies for cancer and autoimmune disease, in-vivo editing for cardiovascular targets, and a stem-cell approach to type 1 diabetes. It is headquartered in Zug, Switzerland.
Where it sits in the stack
Crispr Therapeutics carries no seat in our index and sits outside the AI build-out stack entirely; it belongs to our healthcare universe, in the biotechnology sleeve, as a gene-editing developer rather than an infrastructure or compute name.
Who it is priced against
Closelooknet has not set a peer group for this name; the comparison the market draws most often is with Intellia Therapeutics, another CRISPR-based drug developer.
Why Closelooknet tracks it
It holds no index seat and carries no Closelooknet score. Its only diary mentions come from strategy and heresy pieces citing the CRSP database behind Bessembinder's stock-return study, a reference to the academic dataset rather than coverage of the company itself.
What the diary watches
The diary watches how the Vertex partnership evolves and whether Casgevy's uptake and the wider pipeline's clinical progress eventually earn the name its own index seat and score.

Crispr Therapeutics AG (CRSP) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

FAQ · from the current data · as of 2026-10-31

Quick answers

What is Crispr Therapeutics AG (CRSP)?

Crispr Therapeutics AG trades as CRSP on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-31.

Is CRSP in a Closelooknet index?

Not currently — Crispr Therapeutics AG is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-31.

Where does CRSP trade against its moving averages?

Crispr Therapeutics AG trades 5.1% below its 50-day and 2.8% below its 200-day moving average (0.2% below its 20-day). As of 2026-10-30 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Crispr Therapeutics AG compare with its peers?

Against its peer group (Biotechnology · US), Crispr Therapeutics AG (CRSP) sits 22.1% below its 52-week high, 5.1% below its 50-day average; Halozyme Therapeutics Inc (HALO) is 2.3% below, BeiGene, Ltd. (ONC) is 4.7% below, argenx NV ADR (ARGX) is 16.8% below, as of 2026-10-30. Put any of them next to CRSP in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Crispr Therapeutics AG trade when bond yields rise?

Over the past year Crispr Therapeutics AG had a beta of 1.63 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 97% of US names. On the 10 sessions in which long bonds fell most it moved −2.60% on average, against −0.74% for the S&P 500. As of 2026-10-30; The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about Crispr Therapeutics AG?

Crispr Therapeutics AG appears in 2 Closelooknet pieces as of 2026-10-31, most recently Strategy: Portfolio Construction — The Barbell Architecture, Why the Middle Is Decay (2026-05-23); Heresy: US Equities — Don’t Buy U.S. Stocks · Closelooknet Heresy (2026-05-08). What Closelooknet said most recently: Bessembinder's 2018 paper showed that, of the US common stocks in the CRSP database from 1926 to 2016, the best-performing 4% accounted for the entire net wealth ever created — the other 96% collectively matched one-month Treasury bills. (Strategy, 2026-05-23). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

What does Crispr Therapeutics AG do?

Crispr Therapeutics builds gene-editing medicines around its CRISPR/Cas9 platform, altering specific DNA sequences to treat serious diseases. Its lead product, Casgevy, edits a patient's own stem cells to treat sickle cell disease and beta-thalassemia, developed with partner Vertex Pharmaceuticals. The pipeline extends into CAR T cell therapies for cancer and autoimmune disease, in-vivo editing for cardiovascular targets, and a stem-cell approach to type 1 diabetes. Closelooknet has not set a peer group for this name; the comparison the market draws most often is with Intellia Therapeutics, another CRISPR-based drug developer. (Company snapshot of 2026-09-17.)

Where does Crispr Therapeutics AG sit in the AI build-out?

Crispr Therapeutics carries no seat in our index and sits outside the AI build-out stack entirely; it belongs to our healthcare universe, in the biotechnology sleeve, as a gene-editing developer rather than an infrastructure or compute name. It holds no index seat and carries no Closelooknet score. Its only diary mentions come from strategy and heresy pieces citing the CRSP database behind Bessembinder's stock-return study, a reference to the academic dataset rather than coverage of the company itself. (Company snapshot of 2026-09-17.)

What does this page show?

A live price chart with SMA overlays and drawing tools for CRSP, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.